Lotus Pharmaceutical Co., Ltd. (TPE:1795)

Market Cap	61.48B
Revenue (ttm)	19.12B
Net Income (ttm)	5.46B
Shares Out	262.16M
EPS (ttm)	20.73
PE Ratio	11.31
Forward PE	11.76
Dividend	5.73 (2.44%)
Ex-Dividend Date	Aug 5, 2024

Volume	1,117,476
Average Volume	1,789,405
Open	235.50
Previous Close	234.50
Day's Range	232.50 - 236.50
52-Week Range	172.50 - 323.00
Beta	-0.01
RSI	58.86
Earnings Date	May 9, 2025

About Lotus Pharmaceutical

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system diseases. The company also provides over-the-counter products. In addition, it engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemica...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1966
• Employees: 1,099
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1795

Financial Performance

In 2024, Lotus Pharmaceutical's revenue was 18.58 billion, an increase of 9.59% compared to the previous year's 16.96 billion. Earnings were 5.07 billion, an increase of 23.38%.